Ulrik Niels Lassen

Ulrik Niels Lassen

Clinical Professor

Member of:

  • Clinical Oncology


  1. Published

    Patient information in phase 1 trials: A systematic review

    Gad, K. T., Lassen, Ulrik Niels, Mau-Søerensen, M., Høybye, M. T. & Johansen, Christoffer, Mar 2018, In: Psycho-Oncology. 27, 3, p. 768-780

    Research output: Contribution to journalReviewResearchpeer-review

  2. Published

    Socioeconomic Differences in Referral to Phase I Cancer Clinical Trials: A Danish Matched Cancer Case-Control Study

    Gad, K. T., Johansen, Christoffer, Duun-Henriksen, A. K., Krøyer, A., Olsen, M. H., Lassen, Ulrik Niels, Mau-Sørensen, M. & Dalton, Susanne Oksbjerg, 1 May 2019, In: Journal of Clinical Oncology. 37, 13, p. 1111-1119

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Published

    Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers

    Garcia‐foncillas, J., Bokemeyer, C., Italiano, A., Keating, K., Paracha, N., Fellous, M., Marian, M., Fillbrunn, M., Gao, W., Ayyagari, R. & Lassen, Ulrik Niels, 2022, In: Cancers. 14, 7, 15 p., 1793.

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Published

    Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer

    Grunnet, M., Christensen, I. J., Lassen, Ulrik Niels, Jensen, L. H., Lydolph, M., Knox, J. J., McNamara, M. G., Jitlal, M., Wasan, H., Bridgewater, J., Valle, J. W. & Mau-Sørensen, M., Jul 2015, In: European journal of cancer (Oxford, England : 1990). 51, 11, p. 1381-8 8 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Published

    Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin

    Hassan, R., Alewine, C., Mian, I., Spreafico, A., Siu, L. L., Gomez-Roca, C., Delord, J. P., Italiano, A., Lassen, Ulrik Niels, Soria, J. C., Bahleda, R., Thomas, A., Steinberg, S. M., Peer, C. J., Figg, W. D., Niederfellner, G., Méresse Naegelen, V. & Pastan, I., 2020, In: Cancer. 126, 22, p. 4936-4947 12 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  6. Published

    Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial

    Hasselbalch, B., Lassen, Ulrik Niels, Hansen, S., Holmberg, M., Sørensen, M., Kosteljanetz, M., Broholm, H., Stockhausen, M. & Poulsen, H. S., May 2010, In: Neuro-Oncology. 12, 5, p. 508-16 9 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  7. Published

    Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan

    Hasselbalch, B., Eriksen, J. G., Broholm, H., Christensen, I. J., Grunnet, K., Horsman, M. R., Poulsen, H. S., Stockhausen, M. & Lassen, Ulrik Niels, Aug 2010, In: APMIS : acta pathologica, microbiologica, et immunologica Scandinavica. 118, 8, p. 585-94 10 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  8. Published

    Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial

    Hasselbalch, B., Lassen, Ulrik Niels, Hansen, S., Holmberg, M., Sørensen, M., Kosteljanetz, M., Broholm, H., Stockhausen, M. & Poulsen, H. S., 1 May 2010, In: Neuro-Oncology. 12, 5, p. 508-16 9 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  9. Published

    Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan

    Hasselbalch, B., Eriksen, J. G., Broholm, H., Christensen, I. J., Grunnet, K., Horsman, M. R., Poulsen, H. S., Stockhausen, M. & Lassen, Ulrik Niels, 1 Aug 2010, In: Acta Pathologica Microbiologica et Immunologica Scandinavica. 118, 8, p. 585-94 10 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  10. Published

    Cetuximab insufficiently inhibits glioma cell growth due to persistent EGFR downstream signaling

    Hasselbalch, B., Lassen, Ulrik Niels, Poulsen, H. S. & Stockhausen, M., 1 Oct 2010, In: Cancer Investigation. 28, 8, p. 775-87 13 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

Previous 1 2 3 4 5 6 7 8 ...16 Next

ID: 4952653